secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210298
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q1 net loss $44.5M; cash $671M; multiple pipeline advances
---------------------------------------------------------------------

- Net loss of $44.5M vs net income of $46.9M in Q1 2025; collaboration revenue fell to $4.2M from $84.9M.
- Cash, equivalents, and securities total $671.2M as of March 31, 2026, sufficient into 2029; $345M public offering closed in Jan.
- MRT-8102 (NEK7 MGD) showed 85% CRP reduction in elevated CVD risk; Phase 2 studies in ASCVD, gout, and hidradenitis suppurativa planned H2 2026–H1 2027.
- MRT-2359 (GSPT1 MGD): Phase 2 in mCRPC with AR mutations anticipated Q3 2026 after positive interim data; supply deal with Johnson & Johnson.
- Novartis to initiate multiple Phase 2 studies of MRT-6160 (VAV1 MGD) in immune-mediated diseases in 2026; Monte Rosa eligible for up to $2.1B milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/0001193125-26-210298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/glue-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer